LIGHT SWITCH BIO, LLC

Biotech · Private

IR-Platin, a photoactivated chemotherapy prodrug that releases platinum(II) species and singlet oxygen under near-infrared light for localized cancer treatment

Grants
$461K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Light-directed therapy of squamous cell head and neck cancer with a novel dual-acting chemotherapeutic.$406,186
Federal grantDepartment of Health and Human Services · Phase I · Light-directed therapy of squamous cell head and neck cancer with a novel dual-acting chemotherapeutic.$55,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1986LIKARDA LLC——
1987NATURA THERAPEUTICS, INC.——
1988Ultimaxx Health, LLC—$10M
1989LIGHT SWITCH BIO, LLC——
1990Harpoon Therapeutics—$220M
1991NEOKERA, LLC——
1992Primus Pharmaceuticals——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.